Autor(es): KUNTZER T.

Resumo: Several high-quality publications were published in 2013 and some major trials studies were started. In Guillain-Barré syndrome, events included the launch of IGOS and a better understanding of diagnostic limits, the effect of influenza vaccination, and better care, but uncertainty remains about analgesics. A new mouse model was also described. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), diagnostic pitfalls can be recalled. Our knowledge of underlying pathophysiological processes has improved, and the value of monitoring with function and deficit scores has been demonstrated. IVIG can sometimes be effective longer than expected, but CIDP remains sensitive to corticosteroids, particularly with the long-term beneficial effects of megadose dexamethasone. The impact of fingolimod remains to be demonstrated in an ongoing trial. Advances concerning multifocal motor neuropathy, inflammatory plexopathy, and neuropathy with anti -MAG activity are discussed but treatments already recognized as effective should not be changed. Imaging of peripheral nerve progresses.

Palavras-Chave: CIDP; Guillain-Barré syndrome; Inflammatory neuropathy; Neuropathie inflammatoire; PIDC

Imprenta: Revue Neurologique, v. 170, n. 12, p. 850-853, 2014

Identificador do objeto digital: 10.1016/j.neurol.2014.05.011

Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Inflammation

Data de publicação: 2014

INDICADORES

ACESSO